Vile RG - Search Results

1

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.

Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, Brunn G, Thompson J, Chester J, Vile RG. Cole C, et al. Among authors: vile rg. Nat Med. 2005 Oct;11(10):1073-81. doi: 10.1038/nm1297. Epub 2005 Sep 18. Nat Med. 2005. PMID: 16170322

2

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter.

Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Vile RG, et al. Virology. 1995 Dec 1;214(1):307-13. doi: 10.1006/viro.1995.9923. Virology. 1995. PMID: 8525635 Free article.

3

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.

Vile RG, Diaz RM, Castleden S, Chong H. Vile RG, et al. Biochem Soc Trans. 1997 May;25(2):717-22. doi: 10.1042/bst0250717. Biochem Soc Trans. 1997. PMID: 9191190 Review. No abstract available.

4

Euro targeting in Leiden: the fourth meeting of the EWGT, University of Leiden, 14-17 November 1996.

Diaz RM, Vile R. Diaz RM, et al. Gene Ther. 1997 Jun;4(6):501-3. doi: 10.1038/sj.gt.3300445. Gene Ther. 1997. PMID: 9231064 No abstract available.

5

Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Diaz RM, Eisen T, Hart IR, Vile RG. Diaz RM, et al. Among authors: vile rg. J Virol. 1998 Jan;72(1):789-95. doi: 10.1128/JVI.72.1.789-795.1998. J Virol. 1998. PMID: 9420288 Free PMC article.

6

Strategies for achieving multiple layers of selectivity in gene therapy.

Vile RG, Sunassee K, Diaz RM. Vile RG, et al. Mol Med Today. 1998 Feb;4(2):84-92. doi: 10.1016/S1357-4310(97)01157-X. Mol Med Today. 1998. PMID: 9547795 Review.

7

Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer.

Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Diaz RM, et al. Among authors: vile rg. Gene Ther. 1998 Jul;5(7):869-79. doi: 10.1038/sj.gt.3300690. Gene Ther. 1998. PMID: 9813657

8

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.

Peng KW, Vile R, Cosset FL, Russell S. Peng KW, et al. Gene Ther. 1999 Sep;6(9):1552-7. doi: 10.1038/sj.gt.3300982. Gene Ther. 1999. PMID: 10490764

9

Apoptosis or necrosis for tumor immunotherapy: what's in a name?

Melcher A, Gough M, Todryk S, Vile R. Melcher A, et al. J Mol Med (Berl). 1999 Dec;77(12):824-33. doi: 10.1007/s001099900066. J Mol Med (Berl). 1999. PMID: 10682318 Review.

10

Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.

Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ, Vile RG. Bateman A, et al. Among authors: vile rg. Cancer Res. 2000 Mar 15;60(6):1492-7. Cancer Res. 2000. PMID: 10749110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters